Selective JAK2/ABL Dual Inhibition Therapy Effectively Eliminates TKI-insensitive CML Stem/Progenitor Cells
Oncotarget - United States
doi 10.18632/oncotarget.2353
Full Text
Open PDFAbstract
Available in full text
Categories
Date
August 16, 2014
Authors
Publisher
Impact Journals, LLC